🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
8.23
-0.46 (-5.29%)
Nov 18, 2026, 4:00 PM EST - Market closed
← View all transcripts

Jefferies Global Healthcare Conference

Nov 18, 2026

Summary

RSV is the lead near-term catalyst, with pediatric LOTUS data due in Q1 2027 and adult RESOLVE testing symptom reduction. Immunology milestones include KIT data in Q1 and a STAT6 IND in Q2 2027.

Phoebe Tan
Biotechnology Equity Research Associate, Jefferies

Good afternoon, everyone. Thank you for joining us at the Jefferies London Healthcare Conference. My name is Phoebe Tan, and I work with Akash Tewari at Jefferies. Today, I have the pleasure of hosting Enanta, Jay Luly, the CEO, and Tara Kieffer, the COO.

Jay Luly
CEO, Enanta

Thank you. Before I begin, I want to remind you I will be making some forward-looking statements, and for a summary of the risks associated with these statements, please see our filings on sec.gov and on our website. Opening remarks, what would you

Phoebe Tan
Biotechnology Equity Research Associate, Jefferies

Yeah, anything.

Jay Luly
CEO, Enanta

Yeah. For those of you who are less familiar with us, we are a virology and immunology company. We have historically have come up with a couple of cures with AbbVie for hepatitis C virus and have brought two drugs to patients, curing well over 1 million patients worldwide. We have broadened that into respiratory viruses, and RSV is our key virology program internally right now, the most advanced asset in our pipeline. We have a couple of phase IIs that are One is about to report out next quarter. I am sure we will get into that a little bit, and the other one is just starting. The former is in pediatrics, very young children with RSV who are at high risk, obviously, due to their age, and also a high-risk adult study.

We also have broadened our footprint into I&I space. To that end, a few years ago, we announced our first immunology program was in KIT, going after urticaria and mast cell diseases. Our second immunology program that we announced was in STAT6, and obviously, we are looking for an oral version of DUPIXENT in that drug discovery and development profile. Our more recent program in immunology is MRGPRX2, another mast cell target that could be in various mast cell-driven skin disorders as well as potentially migraines. We just announced a development candidate in that. We have been evergreening the portfolio, laying the seeds each year for the last several years to now be on the cusp of harvesting clinical data from KIT next quarter, and also IND for STAT6 in Q2, and our latest development candidate that we just announced two days ago with an IND in Q4.

Phoebe Tan
Biotechnology Equity Research Associate, Jefferies

Perfect. You just reported your Q4. I just wanted to touch on the pushback of the phase I oral KIT and also the IND for the STAT6. For the phase I, is it any color on maybe enrollment, or is it just dosing delay?

Jay Luly
CEO, Enanta

Yeah, no. The KIT, previously, we had guided that we would have that data by the end of this year, 2026, and it got pushed into Q1. It was mainly just wrapping up the recruitment and giving the team appropriate time to do data analysis and so forth. On STAT6, the timeline there is, as I mentioned, Q2 for the IND, and that was really a CRO manufacturing time slot move that was there. We have completed all the IND-enabling studies for the STAT6 program, hence the new number for the compound now is EDP-903. It gets an EDP number once we finish IND-enabling studies.

Phoebe Tan
Biotechnology Equity Research Associate, Jefferies

Perfect. I just wanted to discuss the workforce reductions. Was there any sort of impact with that driving the delays? Of the reductions, the one-third, is there anything that you can discuss in terms of where that was focused and what you tried to keep and what you decided to remove?

Jay Luly
CEO, Enanta

Yeah, you're hitting all the headlines. We did do a reduction. It's unfortunate lifecycle of a business. You have to look at everything, sort of stem to stern, evaluate all your options, opportunities along the way. Capital is the lifeblood of this industry, and you just have to figure out where and how to raise it and where and how to spend it. Unfortunately, as we prioritized across the whole pipeline, several things that we were currently doing hadn't really been budgeted in our prior runway, including some of the RSV studies. In order to build those in so that we could have the catalysts that we wanted to really deliver and to also put the right amount of capital on our key assets and give us financial flexibility into the future, we made that difficult decision.

But we do have all the key programs staffed up with the right people.

Phoebe Tan
Biotechnology Equity Research Associate, Jefferies

Okay, perfect. You also recently announced the selected development candidate for your MRGPRX2 inhibitor. Can you just discuss what drove you for that selection and what characteristics you're looking for there?

Jay Luly
CEO, Enanta

Yeah. Maybe I'll let Tara handle that one.

Tara Kieffer
COO, Enanta

Sure. Yeah, we are interested in X2 inhibition for mast cell-related diseases, as well as potentially in migraine. There is a really interesting crosstalk between peripheral meningeal mast cells and neurons that drives that neurogenic inflammation. There has been some interesting clinical data that has suggested that blocking PACAP actually shows efficacy in migraine in a phase II clinical trial. However, when you block the receptor, you do not see any efficacy. It is unknown what the receptor is, and the candidate receptor would be potentially X2. We are very interested in that as well. As you mentioned this week, we recently selected our development candidate, which is EPS-5336. We have shown good potency, subnanomolar potency in cellular assays. We also see that potency across all of the agonists for X2, and then really good selectivity as well, against other GPCRs.

We also use a non-competitive mechanism of inhibition, which should be effective, is important because it should be effective even in conditions where the local concentration of ligand may be high. That is in contrast to a competitive inhibitor, where that may be impacted because you can out-compete the inhibition. We have some really interesting data generated on this compound. To our knowledge, it is the first type of data that anyone has generated where we have looked at peripheral, looked at meningeal mast cells from post-mortem donors and shown that our candidate, EPS-5336, can inhibit PACAP-induced degranulation in those meningeal mast cells. So it is a

Phoebe Tan
Biotechnology Equity Research Associate, Jefferies

Great

Tara Kieffer
COO, Enanta

it is exciting program, and we have guided towards an IND for that program in the fourth quarter of next year.

Phoebe Tan
Biotechnology Equity Research Associate, Jefferies

Okay, perfect. Just a follow-up question on that. Is there, in terms of translation from preclinical to human, is there anything that gives you additional confidence there?

Tara Kieffer
COO, Enanta

I think showing that inhibition again in those meningeal mast cells, it's obviously tissue that's relevant to migraine. We've also shown in an animal model that we, in the skin, we can also suppress degranulation of skin mast cells. I think that's important data that can be hopefully translated into the clinic once we get into patients.

Phoebe Tan
Biotechnology Equity Research Associate, Jefferies

Great. Before moving on to RSV, I wanted to touch on the CEO search. Just if there's any sort of qualities that you're looking for in your next search.

Jay Luly
CEO, Enanta

We want the CEO to be a sterling candidate. Yeah, so for those of you who don't know, I announced my retirement a few weeks ago that I'll be retiring by February 1. The board has instituted a search of internal candidates as well as external candidates, and so that process is very much ongoing. Tara Kieffer, to my side, was recently promoted to Chief Operating Officer, so we've got a very strong bench at Enanta, and again, the team's firing on all cylinders. So we'll find a proper candidate that will, again, carry on. The mission really hasn't changed. Pipeline's got very key objectives. We've got a number of key events driving that pipeline in 2027 and the right team around it to do it. So it's a process, and we expect it to be concluding sometime next year, early next year.

Phoebe Tan
Biotechnology Equity Research Associate, Jefferies

Got it. Thank you. Turning to RSV, you've completed enrollment for the phase II-B LOTUS trial, and that's in pediatrics. That'll read out Q1 of next year. Currently, the trial is using RESOLVE-P, a score you developed. Just what is your bar for success there in terms of the top-line results that we'll get and also what you want to see to give you confidence?

Tara Kieffer
COO, Enanta

Sure. Just as a reminder, the LOTUS study is in pediatric patients. It is 150 patients, aged 28 days to 36 months, looking for patients that have had symptom onset within three days. The primary endpoint there is time to complete symptom duration, sorry, time to complete symptom resolution as measured by our own proprietary tool, which is RESOLVE-P. In terms of what we are looking for, I think there is not a lot of good benchmarks in RSV because there are no approved treatments, not much in the way of phase III studies. We can look to other respiratory infections like flu, influenza, and COVID. The approved antivirals that have been approved on symptom endpoints, like TAMIFLU or XOFLUZA in flu or ensitrelvir for COVID, have shown anywhere from about 13%-33% reduction in symptoms.

That gives us a bit of a ballpark in terms of what we are looking for. In RSV, I think that where we can point to there is our own data. In the adult population, we showed about a 35% reduction in symptoms. In pediatrics, our previous phase II study, we did not have data from the RESOLVE-P tool, but we used a different tool called ReSViNET, which is publicly available. Not really a fit for purpose in terms of looking longitudinally for symptoms, but when we used it and in a post-hoc analysis, showed about a 19% reduction in symptoms. So that gives kind of a guidance around where we are looking to see.

Phoebe Tan
Biotechnology Equity Research Associate, Jefferies

Perfect. For your phase III, I know we are waiting for the phase II, but just in terms of what that registrational pathway might look like, is there anything that you want to see in phase II that might affect what you would do in phase III?

Tara Kieffer
COO, Enanta

For pediatrics?

Phoebe Tan
Biotechnology Equity Research Associate, Jefferies

Yes.

Tara Kieffer
COO, Enanta

Right. I think the information we'll get from the phase II will give us a treatment effect size using that RESOLVE-P tool. That will be really important to understand then how to design and power our phase III to show a statistically significant effect on symptoms. The phase II, as I mentioned, is only 150 patients, so not necessarily powered to see significance there, but we'd be looking to understand what the treatment effect is.

Phoebe Tan
Biotechnology Equity Research Associate, Jefferies

Okay. Got it. You've also initiated dosing on your phase IIb/III RESOLVE study. That's in adults, and that will be You've done it in a high-risk population that's similar to the RSV HR, high-risk III population subgroup. I guess for powering assumptions, is it safe to say that what you saw in phase II is what you're hoping to see in phase III? Or how should we be thinking about powering there?

Tara Kieffer
COO, Enanta

The RESOLVE study, as you mentioned, is the phase IIb/III. We are, for that phase IIb portion, looking to recapitulate the data that we saw in our previous phase II, which was RSV HR. As a reminder, that was in the HR III subset of patients, and HR III includes people that are older than 75 or those that have congestive heart failure or COPD. In that group, we saw about a seven-day or 35% reduction in time to symptom resolution. We'd be looking to recapitulate that in this IIb portion, which is exclusively looking at that HR III population with a primary endpoint of time to complete symptom resolution as measured with a tool called RIIQ.

That section, that portion of the study is about 200 patients. We're not expecting to see statistical significance. It's not powered, but it's more to confirm both the endpoints and the sizing for the phase III. The phase III portion is about 600 patients, so it's much bigger, and that is powered to show a statistically significant reduction in symptoms.

Phoebe Tan
Biotechnology Equity Research Associate, Jefferies

Got it. Your secondary is hospitalizations or reductions in hospitalizations. Given that that's probably not powered as well in the phase II section, what are you looking for there to give you support for phase III?

Tara Kieffer
COO, Enanta

Right. In the previous study, we showed a reduction in hospitalization. In the placebo arm, we saw a 5% hospitalization rate, and then in RSV-associated hospitalizations with a treatment, it was 0%. If we're able to repeat that in this upcoming IIb portion, I think that would be very powerful, and that's something that we could potentially show statistical significance on then in phase III. We'll have to see what the data looks like. It was small numbers in the original study.

Again, if we're able to sort of confirm that, it gives much more confidence going into phase III.

Phoebe Tan
Biotechnology Equity Research Associate, Jefferies

Perfect. Just comparing your phase IIb RSV HR to the RESOLVE study, you did an extended two-day dosing. Can you talk about the rationale behind that and how much you expect that to change?

Tara Kieffer
COO, Enanta

Sure. Yeah, what we noticed in the previous study is that at the end of treatment at day five, there were still some patients that had detectable viral loads. Our thought is, if we could extend that treatment duration by a day or two, might we be able to continue drive down that viral load in those patients and have the potential to translate to an even greater symptom benefit? Given that we've now dosed over 700 patients with zelicapavir, and we have treated up to 21 days in humans, we feel very comfortable with the safety profile. We thought that balanced approach in treating seven days might provide greater benefit.

Phoebe Tan
Biotechnology Equity Research Associate, Jefferies

That makes sense. Also, in terms of your design, you have the patients getting symptoms within three days of onset. When you think about that in real-world practice, how do you think that that translates with a high-risk adult, and how realistically would that diagnosis be?

Tara Kieffer
COO, Enanta

Hmm. We've certainly enrolled within that treatment window. We've done it in our previous studies. I think it's something that physicians are certainly very familiar with and comfortable with in terms of other respiratory viruses that have a similar treatment window. Even patient populations now post-pandemic, I think everyone's much more familiar with testing early and getting treated early. For example, in influenza, those drugs need to be administered within 48 hours of symptom onset. COVID, it's a little longer of a treatment window. It's five days. For RSV, for our treatment, it's three days. I think there's a lot of familiarity with that. The other thing that has sort of changed the field is the availability now of at-home test kits. You can walk down to your local pharmacy and pick up a kit that is a quad panel.

You do one swab and test yourself, and in 15 minutes, you find out whether you've got flu A, flu B, COVID, or RSV. Having that available, I think, will also drive diagnosis and getting patients in earlier for treatment.

Phoebe Tan
Biotechnology Equity Research Associate, Jefferies

Perfect. On RESOLVE's primary endpoint, it includes around 10% vaccinated patients, or up to 10%. I guess, number one, how do you expect the vaccinated patients to do versus non-vaccinated patients? Number two, does this suggest that you could get this on-label perhaps?

Tara Kieffer
COO, Enanta

We think that treatment with zelicapavir should be effective on reducing symptoms even in vaccinated patients that have symptomatic breakthrough. Our goal is to include all eligible high-risk patients in the label. Ultimately, it will depend on the data we see and subsequent regulatory interactions.

Phoebe Tan
Biotechnology Equity Research Associate, Jefferies

Okay. Got it. On EDP-323, it is later, past all the catalysts upcoming, but you also noted that this could be potentially used in combination for RSV treatment. Can you explain the rationale, and what would you need to see in this upcoming dataset or from 323 that might convince you to go forward with that?

Tara Kieffer
COO, Enanta

EDP-323, just by way of reminder, is our L inhibitor, polymerase inhibitor for RSV, where we have shown excellent data in a challenge study setting. We think some of the best data that we have seen in a challenge study. For RSV, I think treatment with a single therapy is probably sufficient for most patients. We have zelicapavir as potentially a first-in-disease treatment. EDP-323 could be a best-in-disease treatment. But we do have the combination potential, as you mentioned. We know that pre-clinically, the two compounds are additive to synergistic. They have different resistance profiles. So they might be beneficial in certain subsets of patients that are more sick or immune-compromised patients that may benefit from two drugs and shortening that treatment duration.

Phoebe Tan
Biotechnology Equity Research Associate, Jefferies

Perfect. That makes sense. In our last five minutes, I will turn to the other pipeline products that you have. Starting with the KIT program, we will get data next quarter. I guess the first is, what do you expect this profile to look like, and how do you think it should compare to current XELJANZ or other treatments already in pipeline or clinic?

Tara Kieffer
COO, Enanta

EDP-978 is our KIT inhibitor that we spoke about in phase I currently. That data readout, again, as you mentioned, is in Q1 of next year. It is a traditional SAD/MAD study. The MAD portion is dosing up to 14 days. We will be able to see safety, tolerability, PK, and then a PD biomarker of serum tryptase. Serum tryptase has been There is a lot of data now tying it to downstream clinical outcomes, so it is a really good way to de-risk your program early on and get a sense of activity. What we would like to see is dose-dependent reductions in serum tryptase up to about 80%.

A safety profile would be expected to be similar to other KIT inhibitors. We do not anticipate any off-target effects, just given the good selectivity we have seen pre-clinically. I think that type of a data package would set us up nicely for a proof-of-concept study in patients where we would enable different dosing strategies in patients.

Phoebe Tan
Biotechnology Equity Research Associate, Jefferies

Perfect. For the phase I data with the tryptase, some people, because we used to cover Third Harmonic, so some people would say you need really deep reduction, 100% reduction in tryptase, and some say there is a threshold. I guess, what is your view here?

Tara Kieffer
COO, Enanta

Yeah, it's interesting. I think either could be the case, and we really have to understand it clinically. It might be that you don't need full suppression in patients, and that getting something like 80%, 60%, less percent reduction in serum tryptase still gets you the really good efficacy that has been seen with the anti-KIT antibodies. The idea is if you can get by with less inhibition and still maintain that efficacy, you might be able to mitigate some of the known on-target side effects that come along with KIT inhibition. That's something we're very interested in testing in the clinic in patients.

Phoebe Tan
Biotechnology Equity Research Associate, Jefferies

Perfect. I know you touched on this already, but just on Third Harmonic, there was some liver tox, and that had issues with the program. How de-risked do you think the preclinical data that you're seeing can be for the human data?

Jay Luly
CEO, Enanta

Yeah, the Third Harmonic molecule had reactive metabolites, and we had predicted they would have some issues there, and in fact, they did. We screen out reactive metabolites in pretty much all of our drug candidates, regardless of what program it is. I think that's a difference.

Phoebe Tan
Biotechnology Equity Research Associate, Jefferies

Got it. Just on the top line that we'll get, how much information should we expect?

Tara Kieffer
COO, Enanta

We'll have safety, tolerability, PK, and then for both SAD and MAD portions, and we'll get serum tryptase as well.

Phoebe Tan
Biotechnology Equity Research Associate, Jefferies

Perfect. Moving on to your STAT6, we'll also be getting data, or it'll be getting into IND. How do you think that this differentiates versus other existing programs?

Tara Kieffer
COO, Enanta

EDP-903 is our clinical candidate, and it's shown really good preclinical data in terms of being able to inhibit phosphorylated STAT6. We've shown a rapid, complete, and continuous suppression over a 24-hour period after oral dosing in a mouse. We've also shown efficacy comparable to dupilumab in a number of animal models of disease, including atopic dermatitis and asthma. I think that data has been quite compelling. As Jay mentioned, we've completed all the IND-enabling activities, and we're moving towards IND in the second quarter of next year.

Phoebe Tan
Biotechnology Equity Research Associate, Jefferies

Perfect. On the preclinical data, it looks pretty encouraging with a 90% pSTAT6 inhibition at 24 hours in mice. How do you expect that to translate to the data in humans as well?

Tara Kieffer
COO, Enanta

Mm-hmm. We're targeting a once-daily human dose that covers the EC90, and we've been able to show in preclinical species that distribution to the skin appears similar to what we see in the plasma. It's definitely achievable.

Phoebe Tan
Biotechnology Equity Research Associate, Jefferies

Great. It's coming kind of behind the other assets, so I guess where do you think that you can either, not make up ground, but see where you could get some market share potentially, like later down the line?

Tara Kieffer
COO, Enanta

What we've done with EDP-903 is to try to select something that has best-in-class potential. It's obviously a large market, a large field. We've seen already some of these go by the wayside, so I think you keep pushing forward, and we hope we've designed a really good molecule.

Phoebe Tan
Biotechnology Equity Research Associate, Jefferies

Great. Lastly, on your newly selected EPS-5336, I guess it's very early, but when you go past the IND, what kind of phase I are we looking for, and what developmental projected kind of expectations should we see there?

Tara Kieffer
COO, Enanta

Mm-hmm. A phase I would just be a traditional dose-finding study, SAD/MAD in healthy volunteers. Then we have the potential to go down different development paths, whether that be in urticaria or other mast cell diseases. As I mentioned earlier, I think there is a really interesting potential in migraine. It is an area of high unmet need, and this is sort of coming at it a little bit tangentially from how other treatments are either approved or in development paths. I think it is an interesting opportunity.

Phoebe Tan
Biotechnology Equity Research Associate, Jefferies

Perfect. I think we are right out of time, but thank you so much.

Jay Luly
CEO, Enanta

Thank you.

Tara Kieffer
COO, Enanta

Thank you.